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Summary Comparative genomic hybridization was applied to detect and map changes in DNA copy number in 24 well or moderately
differentiated epithelial ovarian carcinomas (eight serous, eight mucinous and eight endometrioid carcinomas). Twenty-three of the 24
tumours showed changes in DNA copy number in one or several regions (median 4, range 1-17). Gains were more frequentthan losses (ratio
1.6:1.0). The most frequent gains occurred in chromosomes 1q (38%), 2p (29%), 7q (25%), 8q(38%) and 17q (38%), and the most common
losses were located in chromosomes 8p (21%), 9p (25%) and 13q (21%). High-level amplifications were detected in seven tumours at
1q22-32, 2p15-22, 3qcen-23, 6p21-22 and 8q. In the three histological subtypes the copy number karyotypes showed substantial
differences. Gains at 1q were observed in endometrioid (five cases) and serous tumours (four cases). Increased copy number at 1Oq was
seen in endometrioid tumours only (four cases), whereas gains at 11q occurred mostly in serous tumours (four cases). In mucinous tumours,
the most common copy numberchange was a gain at 17q (six cases). The results showthat, in epithelial ovarian carcinoma, changes in DNA
copy number are a rule rather than an exception, chromosomes 1, 2, 7, 8, 9, 13 and 17 being the most frequently affected. The diverging
pattern of genetic changes seen in epithelial ovarian carcinomas with different histological phenotypes suggests that various pathways may
lead to tumorigenesis and/or progression in these subgroups.
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About 90% of ovarian cancers originate from the gonadal epi-
thelium. The majority of ovarian carcinomas are histologically
serous, mucinous or endometrioid, classified according to the
epithelial component. It is not known whether these histological
subtypes share common genetic pathways during tumorigenesis.
Treatment ofthese different subtypes follows the same principles.
The studies by Makar et al (1995) show that endometrioid tumours
have the best prognosis whereas serous tumours make up the
majority and carry an intermediate prognosis. Mucinous tumours
have the poorest outcome, probably due to resistance to
chemotherapy (Makar et al, 1995).
Complex genetic rearrangement is typical of moderately and
poorly differentiated but not of well-differentiated ovarian carci-
noma (Whang-Peng et al, 1984, Pejovic et al, 1992). Molecular
genetic analyses of ovarian carcinoma have suggested a geno-
type-phenotype correlation. Mutation of the KRAS proto-onco-
gene is common, being more frequent in mucinous carcinoma than
in serous carcinoma (Enomoto et al, 1990; Mok et al, 1993;
Ichikawa et al, 1994). Ofthe known tumour-suppressor genes, the
high incidence ofp53 gene point mutations, present in some 50%
ofthese tumours, is found in epithelial ovarian carcinomas (Marks
et al, 1991). Such mutations have also been reported to occur in
more than half ofthe serous carcinomas, in about one-third of the
endometrioid carcinomas, but not in the mucinous carcinomas
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(Klemi et al, 1995). However, this finding has not been seen in all
studies (Bosari et al, 1993; Kohler et al, 1993). There seems to be
a complete lack of mucinous subtype among BRCAI-associated
hereditary ovarian carcinomas (Takahashi et al, 1995).
Karyotype analysis, allelotyping, Southern blotting and gene
expression studies have been performed to identify oncogenes and
tumour-suppressor genes involved in ovarian carcinogenesis.
Recently, comparative genomic hybridization (CGH) has been
developed to survey entire genomes for DNA sequence copy
number variation (Kallioniemi et al, 1992). CGH enables
screening for gains and losses of DNA sequences along all the
chromosome arms. The method is based on the concept that chro-
mosomal regions with an increased copy number reveal dominant
oncogenes, whereas regions with a decreased copy number indi-
cate putative tumour-suppressor gene loci (Kallioniemi et al,
1992). We used CGH to identify and map changes in DNA
sequence copy number in the three most common histological
subtypes of epithelial ovarian carcinoma to find out whether the
different subtypes diverge with respect to the DNA copy number
karyotype.
MATERIAL AND METHODS
Tumour specimens
The material consisted of 24 epithelial ovarian cancers: eight
serous cystadenocarcinomas, eight endometrioid carcinomas and
eight mucinous cystadenocarcinomas of various stages, diagnosed
and treated at the Department of Obstetrics and Gynecology,
Helsinki University Central Hospital, Helsinki, Finland (Table 1).
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Table 1 Histopathological characteristics and DNA copy number changes detected by comparative genomic hybridization in 24 primary ovarian carcinomas
Case Histological Stage Grade Copy number changes
no. subtype
17 Serous 2 +1p22-31, +1q22-qter, +2q21-33, +3p12-q26, +5p, +6p, +6qcen-q21, -7p21-pter, +7q21-35, +8q13-qter,
+11q13-qter, -13q12-32, -17p, -17qcen-q21
22 Serous III 2 +2p11-16, -4q27-32, +8q24-qter, -13q21-31, +17qcen-q21
38 Serous III 1 +8q21-qter, -9p21-pter, +12q, -Xq2l-qter
40 Serous 2 +llqcen-q13,-13q22-31, +16, +17p, +17qcen-q21,-18q12-22
87 Serous II 1 +1q31-41
106 Serous III 2 +1p32-qter, +2p11-pter/2p15-22, -5p15-pter, +7, -8p21-pter, -9p12-pter, +llq, +12p11-q22, +14q21-24, +18p
113 Serous 2 +2p, -2q24-qter, +3p14-24, +5p14-pter, -5q14-qter, -6q22-qter,-9p21-23, -11q23-qter, +13q22-qter,
+14q21-qter, -15q21-qter, -17q, +Xp, +Xqcen-q13
125 Serous II 1 +1q23-qter, +2p13-pter, +2q12-21, +3q22-qter, +4qcen-21, +5p14-15, +6p/6p21-22, +6qcen-q21, +7p21-pter,
+7q21-32, -8p, -8q21-22, +8q24-qter, +1Op, +11q13-22, +12pcen-pl3, -17p, +Xq2l-26
49 Endometrioid 1 +7, -8p21-pter, -13q22-qter, +17qcen-21
77 Endometrioid II 2 No changes
80 Endometrioid 1 +1q,-5q12-21, +8q, +11q12-22
82 Endometrioid III 1 +1q/1q23-41, +3p21-q27/3qcen-q23, +10q23-qter
95 Endometrioid III 1 +1q, +2p21-q23, -8p21-pter, +10
118 Endometrioid II 1 +lq, +7, +8, +10pcen-p12, +10q, +12, +14q, +18q, +Xp2l-pter, +Xql3-23
122 Endometrioid 1 +lq/lqcen-q32, +2, +10, -18p11-pter
127 Endometrioid II 1 -2q22-24, -4p13-15, -4q13-qter, -5q12-21, -8p, +8q, +9q, -10, -12p, +13q12-14, -15q15-qter, -18
2 Mucinous 1 +17
5 Mucinous 1 +8p21-pter, +8q23-qter, -9p13-22, +12q23-qter, +16, +17, +18pcen-pl1, -18q12-22
48 Mucinous 1 -5p15-pter,-5q11-12, +17
74 Mucinous III 2 -2p23-pter, -3p, -3q11-qter, +6pcen-p22/6p21, +7q, +8q, -9p13-pter, -11qcen-q23, +12p11-12, +16q,
-17p12-pter, -X
100 Mucinous 1 +17qcen-q21
111 Mucinous 2 -13q14-qter, +17q
116 Mucinous 1 +2, +3p, -9p21-pter, -16, -17p12-pter, +17q, -Xp, -Xqcen-ql13
119 Mucinous ill 1 -16q22-qter
Gains are marked with + and losses with-. High-level amplifications are in bold type.
High molecular weight tumour DNA was isolated from frozen
tumour sections (22 cases) or archival paraffin-embedded samples
(two cases, samples no. 22 and no. 38).
Comparative genomic hybridization
CGH was performed as described previously (Kallioniemi et al,
1992, 1994), with slight modifications. Briefly, tumour DNA and
normal DNA were labelledby nick translation withbiotin-l4dATP
(Gibco BRL, Gaithersburg, MD, USA) and digoxigenin-ll-dUTP
(Boehringer Mannheim, Mannheim, Germany). Equal amounts
(400 ng) ofthe labelled tumour and normal DNA were hybridized
to normal metaphase spreads for2-3 days. Afterhybridization, the
preparations were washed to remove the unbound DNA. Tumour
DNA was identified with tetra-rhodamine isothiocyanate
(TRITC)-conjugated avidin and normal DNA was detected with
fluorescein isothiocyanate (FITC) anti-digoxigenin. The slides
were counterstained with 4,6-diamidino-2-phenylindole (DAPI)
and covered with antifade solution (Vectashield, Vector
Laboratories, Burlingame, CA, USA) for the identification of the
chromosomes.
Digital image analysis
The hybridizations were evaluated using a Leitz fluorescence
microscope and the isis digital image analysis system
(MetaSystems, Altlussheim, Germany) based on high sensitivity,
integrating a monochrome charge-coupled device camera and an
automated CGH analysis software package. Three-colour images,
red (TRITC) for tumour hybridization, green (FITC) for normal
reference DNA hybridization and blue (DAPI) for DNA counter-
stain were acquired from five to ten metaphase spreads per
hybridization. The fluorescent background was reduced by auto-
matic background correction. The homogeneous background
allowed chromosome segmentation by thresholding of the DAPI
image. Chromosomes were identified and karyotyped on the basis
oftheirDAPI-banding patterns. Red and green fluorescence inten-
sities were measured and the red-to-green ratio profiles along the
medial axis from p- to q-telomere were displayed. For normaliza-
tion ofratio profiles, the modal value ofthe red-to-green ratio for
the entire metaphase was set to 1.0. This was repeated to analyse
the profiles of all the metaphases to be included in the analysis.
The individual ratio profiles were combined using separate
normalizations of p- and q-telomeres to yield the average ratio
profiles that were displayed simultaneously next to the idiograms,
with significance intervals of0.85 and 1.17 respectively.
Interpretation of results and quality controls
Interpretation of CGH results followed the previous protocols
(Kallioniemi et al, 1992, 1994). The red-to-green ratio alterations
along the chromosomes were considered to reflect changes in the
DNA sequence copy number in the tumour genome. The chromo-
somal regions in which the red-to-green ratio exceeded 1.17 were
considered to be over-represented (gains), whereas the regions in
which the ratio was below 0.85 were considered under-represented
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Figure 1 Gains and losses of DNA sequence copy number using comparative genomic hybridization in 24 epithelial ovarian carcinomas. Gains are shown on
the right and losses on the left of the chromosomes. Each line represents genetic aberration seen in one tumour. High-level amplifications are displayed in bold.
Serous tumours are marked with a continuous line (-), mucinous tumours with a dotted line (--- -) and endometrioid tumours with a broken line (.)
Chromosomes 19 and 20 are excluded from the analysis
(losses). If the red-to-green ratio exceeded 1.5 in a small segment
of a chromosome arm, the regions were considered to represent a
high level of DNA amplification. A positive control experiment
with a sample of known chromosomal aberrations was used to
measure the reliability of the method. Hybridizations of normal
female DNA and normal male DNA were used as negative
controls. In the negative controls, the red-to-green ratio remained
between 0.85 and 1.17. The controls were used for each hybridiza-
tion. Chromosomes 19 and 20 were omitted from the analysis
because some apparently abnormal ratios were detected in the
negative controls. The telomeric and heterochromatic areas were
also excluded from the analysis (Kallioniemi et al, 1994).
RESULTS
DNA copy number changes were identified in 23 of the 24
tumours (96%). On average, six copy number changes occurred
per tumour (range 1-17, s.d. 4.7). The only tumour without any
detectable DNA copy number changes was a moderately differen-
tiated endometrioid adenocarcinoma (Table 1). Gains of DNA
sequences were 1.6 times more frequent than losses. Increased
copy number, detected in 9 of the 24 cases (38%), was most
frequent at lq, 8q and 17q (Figure 1). The minimum overlapping
regions were lq31-41, 8q24 and 17qcen-21. Other common
regions with gains were 2p13-16, seen in 7 of24 cases (29%), and
7q21-32, found in 6 of the 24 cases (25%). High-level amplifica-
tions occurred in seven tumours (29%). Six tumours (25%) had a
single amplification whereas one tumour had two highly amplified
regions. The most common regions with copy number losses were
9p, found in 6 of the 24 tumours (25%), and 8p and 13q, both
detected in 5 of the 24 tumours (21%) (Figure 1). The minimum
overlapping regions were 9p2l-22, 8p21-pter and 13q22-31.
In serous tumours, the most common regions with increased
copy number were lq31-41, 2pl3-15, 8q24-qter and llql3,
found in four of eight cases. Two high-level amplifications were
detected, one at 2p15-22 and the other at 6p2l-22. DNA sequence
losses were most frequent at 9p21-pter and 13q22-31, both found
in three ofeight cases.
In mucinous tumours, the most common region with an
increased DNA copy number was 17qcen-21, detected in six of
eight tumors. One high-level amplification was found at 6p21. The
most common loss was at 9p2l-23, found in three ofeight cases.
In endometrioid tumours, the most common regions of gains
were lq and 10q23-qter. Four of eight tumours contained regions
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Figure 2 Comparison of the serous, endometrioid and mucinous subtypes of
ovarian carcinoma with respect to DNA sequence gains at chromosomes 1,
10, 11 and 17. Each line represents genetic aberration detected in one
tumour. High-level amplifications are displayed in bold
with high-level amplifications. The region lq22-32 was amplified
in three tumours. One of these also had a high-level amplification
at 3qcen-23. In one tumour, a high-level amplification was
detected at 8q. Lost regions were found most frequently at
8p2l-pter, in three of eight tumours.
The three different histological subtypes diverged from each
other with respect to copy number karyotype. Gains at 1q occurred
in serous and endometrioid tumours only. Increased copy number
at 10q was detected in endometrioid tumours only, whereas llq
gains appeared mostly in serous tumours and in one additional
case with endometrioid histology. Gains at 17q were most frequent
in mucinous tumours, occurring only twice in serous and once in
endometrioid tumours (Figure 2). Losses at 9p were observed in
serous and mucinous tumours but not in endometrioid tumours,
and losses at 8p were detected in serous and endometrioid tumours
but not in mucinous tumours.
DISCUSSION
In our analysis, 23 of the 24 tumours had several DNA copy
number changes irrespective ofthe histological subtype. However,
the most important finding was that the three major subtypes of
ovarian carcinoma have different copy number karyotypes. In
serous tumours, DNA copy number changes were almost twice as
frequent as in endometrioid and mucinous tumours. Recurrent
gains at 17q were frequent in mucinous tumours but rare in serous
and endometrioid adenocarcinomas, whereas gains at lq, 1Oq and
llq were frequent in serous and endometrioid tumours but non-
existent in mucinous tumours. The well-differentiated tumours
displayed equal frequency of DNA copy number changes
compared with moderately differentiated tumours, indicating
that genetic rearrangements are common in well-differentiated
tumours also.
Our results concur with those of previous studies (Iwabuchi et
al, 1995; Arnold et al, 1996) in showing gains at lq, 2q, 3q, 7q, 8q
and llq, and losses at 8p, 13q and 17p. All high-level amplifica-
tions detected at lq occurred in endometrioid tumours. Gains and
high-level amplifications at lq were seen in the chromosomal
regions where no currently known oncogenes are located.
Therefore, the significance of these changes for malignant trans-
formation cannot yet be explained.
In addition to the above findings, we detected gains at 17q and
losses at 9p. Indeed, gains at 17q were the major copy number
change in mucinous adenocarcinoma. This is of particular interest
because the ERBB2/NEU proto-oncogene is mapped to 17q12 and
is amplified and overexpressed in 25-30% of ovarian carcinomas
(Slamon et al, 1989; Berchuck et al, 1990). According to the liter-
ature, the correlation between the amplification of ERBB2/NEU
and histological subtype is open. Medl et al (1995) found amplifi-
cation of ERBB2/NEU in 35% of serous tumours and 50% of
mucinous tumours, but the difference was not statistically signifi-
cant. On the other hand, Hruze et al (1993) did not find any corre-
lation between copy number of ERBB2/NEU and the histological
subtype. Cells overexpressing the ERBB2/NEU proto-oncogene
display decreased sensitivity to cytotoxic effects of cisplatin in
vitro (Pietras et al, 1994), which perhaps could explain why muci-
nous adenocarcinomas are often resistant to cisplatin. Because
CGH is able to show only amplicons of several megabases, it is
possible that the cases without the amplicon evaluated by CGH
still have ERBB2/NEU amplification.
Losses of DNA sequence at 9p occurred in serous and mucinous
adenocarcinomas. The minimum overlapping region narrows to
9p2l-22, the segment that contains the tumour suppressor gene
p16. Given that homozygous deletions of this gene have been
reported in ovarian carcinoma cell lines (Kamb et al, 1994), and
loss of heterozygosity (LOH) of 9p has been found in ovarian
tumours (Chenevix-Trench et al, 1994), our finding indicates that
loss of this tumour-suppressor gene may not be uncommon in
ovarian carcinoma.
In our analysis, 8q, with two minimal amplification units at
qcen-q 13 and q24-qter, was among the most frequently amplified
regions. Compared with the results of Iwabuchi and co-workers
(Iwabuchi et al, 1995), gains at 8q were more frequent in well and
moderately differentiated carcinomas in our material (11% vs
38%). The minimum overlapping region 8q24 is known to harbour
the CMYC oncogene, amplified in ovarian carcinoma (Sasano et
al, 1990). The more centromeric amplicon 8q 11-12 contains
proto-oncogene CLYN, a member of the SRC family (Corey and
Shapiro, 1994). Although this co-localization does not prove that
gains we observed took place in the CMYC oncogene, these
relationships are nonetheless striking. The entire long arm was
affected in six of nine patients with a gain at 8q, suggesting that
other oncogenes may also be involved.
A gain at 10q appeared to be characteristic of endometrioid
carcinoma and a gain at llq was more characteristic of serous
carcinoma. The minimum overlapping region of the gain at 11q
was I1q13, which harbours the proto-oncogene INT2, a member of
the fibroblast growth factor (FGF) family. This proto-oncogene is
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amplified in breast cancer (Tsuda et al, 1989) and in ovarian
cancer (Medl et al, 1995), again an interesting coincidence. In
breast cancer, the amplification of INT2 correlates with a poor
prognosis, but it appears not to predict survival in patients with
ovarian cancer (Medl et al, 1995). Other genes located at llql3
include HSTFI, also a member of the FGF family, PRADI, EMS
and the folate receptor. The role ofthese genes in ovarian carcino-
genesis is still unclear.
In our material, loss ofgenetic material was also found at 8p and
13q. In ovarian carcinoma loss of heterozygosity (LOH) is
common in 3p21-24 (Zheng et al, 1991), distal 6q (Saito et al,
1992; Cliby et al, 1993), 9p2l (Chevenix-Trench et al, 1994),
llpl5 (Zheng et al, 1991; Kiechle-Schwarz et al, 1993), 13q
(Cliby et al, 1993; Dodson etal, 1994; Kim et al, 1994), 17p (Cliby
et al, 1993) and 17q (Cliby et al, 1993). The results of our CGH
analysis not only corroborate the importance of many of these
regions as possible loci of tumour-suppressor genes but they also
reveal chromosomal regions with genetic loss not previously
linked to ovarian carcinogenesis. Loss of DNA sequences at 8p
has previously been detected in poorly differentiated ovarian
tumours (Iwabuchi et al, 1995), whereas our study shows that it
can occur in well and moderately differentiated ovarian carci-
nomas also. In previous studies, LOH of multiple markers at 13q
has been associated with poorly differentiated ovarian carcinoma
(Cliby et al, 1993; Dodson et al, 1994; Kim et al, 1994), and this
study adds well and moderately differentiated adenocarcinomas to
this list. The minimum common deletion unit in our study at
13q22-31 is telomeric to the RBI and BRCA2 genes, suggesting
the involvement of an unknown tumour-suppressor gene in
ovarian carcinogenesis.
We conclude that different histological subtypes of epithelial
ovarian carcinoma have recurrent DNA copy number changes that
vary according to the histological subtype. These findings should,
however, be confirmed with larger numbers ofpatients with each
subtype ofovarian carcinoma. Several regions ofthe genome that
previously have not been suspected to be involved in ovarian
carcinogenesis were found to have gained or lost genetic material,
evidenced by CGH. Only some of the changes in genetic material
were localized to the regions containing known oncogenes or
tumour-suppressor genes. The regions not containing either of
them should be equally interesting and guide future studies on the
nature and role of genetic defects in ovarian tumorigenesis and
progression.
ABBREVIATIONS
CGH, comparative genomic hybridization; DAPI, 4,6-diamidino-
2-phenylindole; LOH, loss ofheterozygosity.
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